Solriamfetol

索安非托

Report date: 2026/03/23 20:03:44
NME

Base Information

Drug NameSolriamfetol
Drug Alias Name盐酸索安非托Solriamfetol hydrochlorideSunosiSUNOSIYKP-10A +[10] 
ClassificationSmall molecules
Mechanisms of Actionnorepinephrine-dopamine reuptake inhibitor
TargetsNorepinephrine transporterDopamine transporter
Therapy Area/IndicationsConduct DisorderAttention Deficit Disorder with HyperactivityDepressive Disorder, Major +[11] 
Global Approved IndicationsNarcolepsyDisorders of Excessive SomnolenceSleep Apnea, Obstructive
Approved Indications in ChinaDisorders of Excessive Somnolence
Original Approved Country/TerritoryUnited States
Original Approved Date2019/03/20
Country/TerritoryCanadaUnited StatesSweden +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSK Biopharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInsignis Therapeutics IncAxsome Therapeutics LtdIgnis Therapeutics (Suzhou) Ltd +[8] 
Inactive CompaniesSiegfried Malta LtdSiegfried AgJazz Pharmaceuticals Plc +[5] 
Active IndicationsConduct DisorderAttention Deficit Disorder with HyperactivityDepressive Disorder, Major +[10] 
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN06BA14
Related LinksWikipediaDrugBankKEGG